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This Value in Health Special Issue describes technology assess-
ment (TA) programs in ﬁve countries. The primary purpose is to
provide information about the ways coverage and related deci-
sions are made in each country, and how TA is used to support
those decisions. For this purpose each article stands on its own.
Individually they are helpful to understand the decision-making
processes, as well as the methods used to assess technology in
these countries. But when the articles are considered together,
they tell us much more.
One immediate observation is the extent to which TA is being
used. These articles describe a very impressive range of programs.
These are not intellectual exercises; they are integral parts of
national decision-making processes. TA has clearly come a long
way from its origins about 30 years ago.
A second observation relates to the diversity of the programs.
Given that all the programs stem from a common source; this is
more surprising. They all have the same motivation, which is to
understand the effects of health-care technologies on important
outcomes. And they all share a commitment to the same
approach, which is that to the greatest extent possible the under-
standing should be based on rigorous evidence and analytical
methods. From this, one might expect the programs to be very
similar, differing only in details dictated by local conditions such
as committee structures. But the differences we see are consider-
ably deeper than just committee structures; they affect such
things as the types of decisions to which TA is applied, the
mandates given to those applying them, the types of outcomes
they should consider, the criteria for drawing conclusions, and
the extent to which the conclusions are binding.
Looking across the spectrum of programs one might wonder
whether the authors are really talking about the same thing. Some
emphasize an analysis of evidence and for all intents and purposes
stop there. Some look more like health economics and outcomes
research. And for others the centerpiece is a cost-effectiveness
analysis. Just what is TA, if it can morph into so many different
forms? Are the programs actually doing very different
things—evidence-basedmedicine (EBM), outcomes analysis, cost-
effectiveness analysis—and arewe being polite to call them all TA?
Does the interpretation of the term “technology assessment” vary
sowidely that in fact there is no such thing?Or does TA encompass
all of these as well as other disciplines, and the different programs
just vary in the extent to which they use them?
Health TA as deﬁned in International Society For Pharmaco-
economics and Outcomes Research’s (ISPOR) Health-Care Cost,
Quality, and Outcomes: ISPOR Book Terms [1] is “a form of
policy research that examines short- and long-term consequences
of the application of a health-care technology. Properties assessed
include evidence of safety, efﬁcacy, patient-reported outcomes,
real world effectiveness, cost and cost-effectiveness as well as
social, legal, ethical, and political impacts” [1]. The breadth of
this deﬁnition clearly argues for the third interpretation in the
previous paragraph—that TA is an umbrella term that encom-
passes a wide variety of applications and methods. But if we
accept this, then what are we to make of the fact that some of the
programs described in this Special Issue only do, for example, an
evaluation of evidence for safety and efﬁcacy? Some of the pro-
grams not only fail to perform a cost-effectiveness analysis; they
are actually forbidden to do so. Should we cast these programs
out of TA, and say that they just practice EBM?
The most obvious resolution to these questions, I believe, is to
recognize that a “full” TA has several different parts, and that
different programs emphasize different parts. But the programs
described in this Special Issue illustrate something more interest-
ing than this. There is an order to the parts methodologically,
making it reasonable to consider them “stages” towards a full TA,
and the different programs have progressed to different stages.
Thus some programs might be considered not just “different,” in
some arbitrary sense, but “further along” toward a full TA.
The four main stages are apparent in ISPOR’s deﬁnition. The
ﬁrst is an evidence analysis—a systematic evaluation of evidence
for a technology and a requirement of good evidence for such
things as coverage, placement on formularies, and afﬁrmative
guidelines. This stage corresponds to the evidence-based guide-
lines (EBGs) part of EBM. The second stage is an outcomes
analysis. In this stage there is an estimation of the magnitude of
the effects of the technology on the desired clinical outcomes (the
“beneﬁts”) and on potential harms such as side effects and risks
(the “risks”). This stage also includes a comparison of beneﬁts
and risks, to determine if the “beneﬁt–risk ratio” is sufﬁciently
high to justify the technology. The third and fourth stages are
analyses of costs and cost-effectiveness; here the researcher esti-
mates the effect of the technology on costs and compares the
clinical effects against the costs to determine if the ratio is sufﬁ-
ciently high. The last stage is the analysis of the ethical and legal
implications of the technology.
The methodological progression of these stages is apparent.
One can not estimate the magnitude of clinical outcomes (stage
2) without ﬁrst evaluating the clinical evidence (stage 1). One can
not compare the costs and cost-effectiveness (stages 3 and 4)
without estimating the effects on the clinical outcomes (stage 2).
And one can not think about ethical and legal implications of the
technology (stage 5), until one knows something about the costs
and cost-effectiveness (stages 3 and 4).
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That seems ﬁne. But it still begs the question of why different
programs stop at different stages? The most obvious reason is
that as a TA progresses from stage to stage there is more work to
be done. It is easier, faster, and less expensive to simply do an
analysis of the evidence and stop there. Another reason is that the
methods for estimating the magnitudes of clinical beneﬁts, esti-
mating the magnitude of costs, and comparing them, are not
nearly as straightforward or universally accepted as the methods
for evaluating evidence (the ﬁrst stage).
But there is also a third reason. It is that these stages are not
only ordered methodologically, they are also ordered in terms of
their political and social acceptability. Until very recently the
appropriateness of a technology was determined pretty much by
whatever physicians wanted to do. No further information was
needed. From the point of view of physicians and patients, this is
clearly a highly desirable “methodology” for determining the
coverage of a technology. It puts virtually no restrictions on what
can be done or paid for. Furthermore this method has prevailed
for hundreds of years. People are not only used to it, they are
addicted to it. The ﬁrst stage of a TA, the analysis of evidence, is
not only younger (about 20 years old) but considerably more
restrictive. It says that before a physician can do something there
must be a systematic evaluation of evidence, and only those
things that are supported by good evidence will be paid for. The
second stage, which calls for estimating and comparing the mag-
nitudes of beneﬁts and harms, is even more restrictive. It implies
that there is some threshold beyond which even effective treat-
ments might be denied if the beneﬁt risk ratio is considered too
small. Finally, an explicit consideration of costs is the most
restrictive of all. It explicitly states that effective technologies can
be denied if they are deemed to cost too much. In societies where
for decades few have had to pay directly for their health care, this
is the most obnoxious of all.
So the fact that TA programs in different countries have
progressed to different stages reﬂects not only methodological
concerns but social and political concerns as well. The fact is that
different countries have reached different stages in their social
and political acceptance of the different parts of a TA. Corre-
spondingly, the TA programs in different countries have reached
different stages. In many settings the profession and the public
are not ready for full TAs and the difﬁcult choices (rationing)
they imply. Given the strengths of the methodologists working
around the world, it is almost certainly these social and political
constraints, and not the resource or methodological constraints
that have caused different programs to get stuck at different
phases in their TAs.
A ﬁnal element of TA illustrated by these articles is its relation-
ship to EBM.As already noted, everyTAbeginswith an evaluation
of the evidence for the technology being assessed. In that sense
EBM is a part of TA, the other parts being the estimation of the
magnitudes of the clinical outcomes (outcomes analysis), the
evaluation of costs (economic analysis), the comparison of health
and economic outcomes (cost-effectiveness analysis or CEA), and
an evaluation of ethical factors. But EBM itself has parts [2]. One
is evidence-based individual decision-making (EBID). As the name
implies this type of EBM focuses on the evidence pertaining to an
individual patient and his or her management. As originally
proposed, it emphasizes the education of physicians in how to
bring evidence to bear on decisions about individual patients [3],
and the synthesis of evidence with clinical judgment [4]. The other
part is evidence-based quidelines (EBGs) [5] or more generally
evidence-based policymaking. This part describes the importance
of basing population-based policies like guidelines, coverage poli-
cies, formulary decisions, and performance measurement on evi-
dence and it is this part that stresses the principle that before any
population-based policy can be promoted there should be good
evidence that the policy will be effective and beneﬁcial. Thus the
relationship between TA and EBM can be nicely visualized as a
Venn diagram as is shown in Figure 1.
EBM consists of EBID and EBG, whereas TA consists of the
evidence used in developing EBG, outcomes analysis, economic
analysis, cost-effectiveness analysis, and ethical/legal analysis.
The two overlap at EBM; the principles and methods for devel-
oping EBGs are an integral part of both TA and EBM, but both
TA and EBM use other principles and methods to be complete.
Those of us who believe in TA have been fairly successful in
gaining acceptance for the evidence part of a TA. Every program
described in this series of articles starts off with this aspect of
EBM. The fact that only a subset of programs goes beyond that,
to explicitly estimate the magnitudes of beneﬁts and harms, and
to explicitly incorporate costs, tells us that we have not been
nearly as successful in helping the profession and public under-
stand the value of these other parts of TA. This must be addressed
if TA is to continue to progress and reach its full potential.
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Figure 1 Relationship of evidence-based medicine and technology assessment.
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